Home
Companies
Catalysts
Deep Dives
Nayzilam
midazolam
APPROVED
Drug Profile
Modality
Small molecule
Route
Nasal
Therapy Area
Neurology
Launch
2019-05-01
US LOE
2035-05-01
Peak Sales Est
$200M
Formulations
[{"id":"nayzilam-nasal","doses":"5mg","route":"Intranasal","device":"Nasal spray","setting":"PATIENT
Companies
UCB
(ORIGINATOR)
100%
Mechanism: GABA-A receptor modulator (benzodiazepine)
Expert:
Enhances GABA-A receptor activity for rapid seizure control
Everyday:
Enhances GABA-A receptor activity for rapid seizure control
Targets: ["GABA-A"]
Revenue History
Period
Revenue ($M)
2023
$85M
2024
$112M
Programs (1)
Indication
Stage
Key Study
Regional Status
Acute repetitive seizures
APPROVED
Study 1520
[{"stage":"APPROVED","region":"US","approval_date":"2019-05"}]
Notes
Midazolam nasal spray for acute treatment of seizure clusters in epilepsy patients. First FDA-approved nasal benzodiazepine rescue therapy, offering non-invasive alternative to rectal diazepam.
Data from Supabase · Updated 2026-03-24